Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-Seq of chemical modification patterns for microRNA therapeutic mimics, a case-study on miR-200c, miR-155 and miR34a

ABSTRACT: RNA-Seq of chemical modification patterns for microRNA therapeutic mimics, a case-study on miR-200c, miR-155 and miR34a

PROVIDER: PRJEB72636 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR12654147_1.fastq.gz	Fastqsanger.gz
	ERR12654147_2.fastq.gz	Fastqsanger.gz
	ERR12654148_1.fastq.gz	Fastqsanger.gz
	ERR12654148_2.fastq.gz	Fastqsanger.gz
	ERR12654149_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 102

Similar Datasets

RNA-Seq of chemical modification patterns for microRNA therapeutic mimics, a case-study on miR-200c, miR-155 and miR34a

Project description:We examined the influence of chemical modifications patterns in a set of miR-200c, miR-155 and miR-34a mimics, assessing the regulation of the whole transcriptome in A549 cells. We examined the mimics and provided an initial set of rules for designing miRNA mimics with potency and selectivity similar to an unmodified miRNA duplex.

2024-02-15 | E-MTAB-13801 | biostudies-arrayexpress

RNA-Seq of A549 cells treated with chemical modification patterns for microRNA therapeutic mimics, a case-study on miR-200c

Project description:We examined the influence of chemical modifications patterns in a set of miR-200c mimics, assessing the regulation of the whole transcriptome in A549 cells. We examined 37 mimics and provided an initial set of rules for designing miRNA mimics with potency and selectivity similar to an unmodified miRNA duplex.

2023-12-20 | E-MTAB-12574 | biostudies-arrayexpress

Transcriptomic analysis of hepatocellular carcinoma cell lines HepG2 treated with Sorafenib and transfected with miR-200c-3p inhibitor, and miR-222-5p and miR-512-3p mimics

Project description:Hepatocellular carcinoma (HCC) is one of the most common causes of death worldwide and the fourth most prevalent type of cancer. Whereas curative treatments such as liver transplantation, ablation or surgery are optimal for early stages, only paliative treatments are given to intermediate and advanced stages of the disease. Despite the introduction of immune regulators as first-line treatments for advanced stages, Sorafenib is still the standard of care in the clinical practice. In cell lysates, anti-tumoral properties of Sorafenib were related to upregulation of miR-200c-3p (anti-tumoral miRNA) at 6 hours of treatment and downregulation of miR-222-5p and miR-512-3p (pro-tumoral miRNAs) at 24 hours. We have identified these miRNA biomarkers of Sorafenib treatment response in plasma of patients with advanced HCC treated with Sorafenib. In particular, miR-200c-3p has been related to increased survival benefit whereas miR-222-5p and miR-512-3p have been related to worse prognosis. Our study has sequenced HepG2 cells treated with Sorafenib and miR-200c-3p inhibitor, and transfected with miR-222-5p and miR-512-3p mimics to unravel the molecular pathways governing Sorafenib response

2022-04-28 | GSE201695 | GEO

RNA-Seq of A549 cells treated with chemical modification patterns for microRNA therapeutic mimics, a case-study on miR-200c

Project description:RNA-Seq of A549 cells treated with chemical modification patterns for microRNA therapeutic mimics, a case-study on miR-200c

| PRJEB59605 | ENA

miR-200c induction in BT549 TNBC cells

Project description:We performed microarray analysis on BT549 cells that express miR-200c in a doxycycline (dox)-inducible manner from the miR-200c-TripZ system.

2017-12-20 | GSE108271 | GEO

Effect of miR-200c-3p overexpression on primary human macrophages

Project description:Macrophages constitute a major part of the tumor-infiltrating immune cells and within the tumor microenvironment acquire an alternatively activated, tumor-supporting phenotype. Factors released by tumor cells are crucial for the recruitment of tumor-associated macrophages. In the present project, we aimed to understand the role of miR-200c in the interplay between tumor cells and macrophages. To this end, we employed a coculture system of MCF7 breast tumor cells and primary human macrophages and observed a substantial transfer of miR-200c from apoptotic tumor cells to macrophages, which required intact CD36 receptor in macrophages. We further comprehensively determined miR-200c targets in macrophages by mRNA-sequencing and found numerous migration-associated mRNAs to be downregulated by miR-200c. Consequently, miR-200c attenuated macrophage infiltration into 3-dimensional tumor spheroids. The miR-200c-mediated reduction of infiltration further correlated well with a miR-200c migration signature comprised of four miR-200c-repressed targets (PPM1F, RAB11FIB2, RDX, MSN).

2022-03-30 | GSE195587 | GEO

miR-200c induction in Met-1 mammary carcionma cells

Project description:We performed RNA-seqeuncing analysis on mouse Met-1 cells that express miR-200c in a doxycycline (DOX)-inducible manner from the miR-200c-TripZ system.

2020-05-28 | GSE151320 | GEO

Expression data from differentiating ES cells expressing miR-200c and miR-141

Project description:ES cells express the miR-200 family which becomes down-regulated during the course of differentiation in serum. We generated an ES cell line which expresses miR-200c and miR-141 upon addition of doxycycline. Microarrays were used to gain a global picture of differentiation when miR-200c and miR-141 expression were maintained throughout differentiation through the addition of doxycycline.

2011-09-22 | GSE24289 | GEO

Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma [L1236]

Project description:Several studies have indicated an important role for miR-155 in the pathogenesis of B-cell lymphoma. Highly elevated levels of miR-155 were indeed observed in most B-cell lymphomas with the exception of Burkitt lymphoma (BL). However, the molecular mechanisms that underlie the oncogenic role of miR-155 in B-cell lymphoma are not well understood. To identify the miR-155 targets relevant for B-cell lymphoma, we performed RNA immunoprecipitation of Argonaute 2 in Hodgkin lymphoma (HL) cells upon miR-155 inhibition and in BL cells upon ectopic expression of miR-155. We identified 54 miR-155-specific target genes in BL cells and confirmed miR-155 targeting of DET1, NIAM, TRIM32, HOMEZ, PSIP1 and JARID2. Five of these targets are also regulated by endogenous miR-155 in HL cells. Both overexpression of miR-155 and inhibition of expression of the novel miR-155 target gene NIAM increased proliferation of BL cells. In primary B-cell lymphoma NIAM-positive cases have significant lower levels of miR-155 as compared to NIAM-negative cases, suggesting that NIAM is also regulated by miR-155 in primary B-cell lymphoma. Thus, our data indicate an oncogenic role for miR-155 in B-cell lymphoma which involves targeting the tumor suppressor NIAM.

2015-07-16 | GSE70937 | GEO

Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma [ST486]

2015-02-20 | GSE64484 | GEO